A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Dual Antagonist of EP2 and EP4 Prostanoid Receptors, As Monotherapy and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumours.
Latest Information Update: 05 Feb 2025
Price :
$35 *
At a glance
- Drugs OKN 4395 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Liposarcoma; Malignant fibrous histiocytoma; Malignant-mesothelioma; Mouth neoplasm; Non-small cell lung cancer; Solid tumours; Solitary-fibrous-tumour; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms INVOKE
- 30 Jan 2025 According to an Owkin media release, the first patient has been dosed in its Phase I clinical trial of OKN4395 on January 22, 2025.
- 21 Jan 2025 New trial record